Company intelligence / Profile preview

Verve International

Boston, Massachusetts, United Statesmyverveworld.com ↗

Ownership: Private
Employees: ~274
Development stage: Commercial

Overview

Initial clinical data from the Phase Ib Heart‑2 trial showed that a single infusion of VERVE‑102 led to dose-dependent reductions in PCSK9 protein and LDL cholesterol, with mean LDL-C reduction up to 53% and maximum up to 69% at the highest dose cohort. The program pivoted from VERVE‑101 after a serious adverse event was reported. The pipeline includes additional programs targeting ANGPTL3 and Lp(a), with further updates expected later in 2025.

Therapeutic areas: Cardiovascular
Modalities: Gene therapyCRISPR-based therapyBase editing
Industry: Biotech

Partnerships

Eli Lilly was already a partner before full acquisition; no other major pharma partnerships publicly disclosed as primary collaborators on pipeline assets.

Beyond the preview

Go deeper on Verve International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verve International.

Explore the full profile